Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 1, 2021

Primary Completion Date

March 30, 2026

Study Completion Date

March 30, 2026

Conditions

Histiocytosis

Interventions

DRUG

Vemurafenib

20 mg/kg/day

Trial Locations (1)

RECRUITING

Mother and Child Institute, Warsaw

All Listed Sponsors

collaborator

Maria Sklodowska-Curie National Research Institute of Oncology

OTHER

collaborator

Łukasiewicz Research Network

UNKNOWN

collaborator

Wrocław University of Environmental and Life Sciences

UNKNOWN

lead

Anna Raciborska

OTHER